Denali Therapeutics Inc (4DN)

Currency in EUR
11.77
-0.05(-0.42%)
Closed·
4DN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.7212.01
52 wk Range
9.9730.33
Key Statistics
Bid/Ask
11.76 / 11.88
Prev. Close
11.81
Open
11.95
Day's Range
11.72-12.01
52 wk Range
9.97-30.33
Volume
85
Average Volume (3m)
291
1-Year Change
-45.56%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4DN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Denali Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Denali Therapeutics Inc Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Compare 4DN to Peers and Sector

Metrics to compare
4DN
Peers
Sector
Relationship
P/E Ratio
0.0x−0.5x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x1.8x2.6x
Price / LTM Sales
0.0x8.3x3.2x
Upside (Analyst Target)
0.0%186.1%42.7%
Fair Value Upside
Unlock19.6%5.8%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

4DN Income Statement

People Also Watch

21.54
BEAM
+2.43%
75.25
ACLS
+0.95%
17.590
QBTS
-4.35%
46.25
GH
+1.34%

FAQ

What Stock Exchange Does Denali Therapeutics Inc Trade On?

Denali Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Denali Therapeutics Inc?

The stock symbol for Denali Therapeutics Inc is "4DN."

What Is the Denali Therapeutics Inc Market Cap?

As of today, Denali Therapeutics Inc market cap is 1.72B.

What Is Denali Therapeutics Inc's Earnings Per Share (TTM)?

The Denali Therapeutics Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 4DN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Denali Therapeutics Inc Stock Split?

Denali Therapeutics Inc has split 0 times.

What is the current trading status of Denali Therapeutics Inc (4DN)?

As of 23 Jul 2025, Denali Therapeutics Inc (4DN) is trading at a price of 11.77, with a previous close of 11.81. The stock has fluctuated within a day range of 11.72 to 12.01, while its 52-week range spans from 9.97 to 30.33.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.